Last reviewed · How we verify
PERHEXILINE MALEATE
PERHEXILINE MALEATE is a drug. It is currently FDA-approved (first approved 1974).
At a glance
| Generic name | PERHEXILINE MALEATE |
|---|---|
| Modality | Small molecule |
| Phase | FDA-approved |
| First approval | 1974 |
Approved indications
Common side effects
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| FDA label | Mechanism, indications, dosing, boxed warnings, drug interactions |
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- PERHEXILINE MALEATE CI brief — competitive landscape report
- PERHEXILINE MALEATE updates RSS · CI watch RSS
Frequently asked questions about PERHEXILINE MALEATE
What is PERHEXILINE MALEATE?
PERHEXILINE MALEATE is a Small molecule drug.
When was PERHEXILINE MALEATE approved?
PERHEXILINE MALEATE was first approved on 1974.
What development phase is PERHEXILINE MALEATE in?
PERHEXILINE MALEATE is FDA-approved (marketed).